A Phase 2b/3, Multicenter, Dose-ranging, Randomized, Double-masked, Placebo-controlled Study of XAF5 Ointment for Reduction of Lower Lid Steatoblepharon
Phase of Trial: Phase II/III
Latest Information Update: 06 Jul 2017
At a glance
- Drugs XAF 5 (Primary)
- Indications Subcutaneous fat disorders
- Focus Therapeutic Use
- Sponsors Topokine Therapeutics
- 28 Jun 2017 Status changed from active, no longer recruiting to completed.
- 07 Mar 2017 Planned End Date changed from 1 Nov 2017 to 1 Apr 2017.
- 25 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Nov 2017.